SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project.

Autor:	Ferreiro-Iglesias R; Gastroenterology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. Electronic address: rocioferstg@hotmail.com., Hernández-Camba A; Gastroenterology Department, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain., Serrano Labajos R; The Spanish Confederation of Crohn's & Colitis Associations (ACCU Spain), Madrid, Spain., Rodríguez-Lago I; Gastroenterology Department, Hospital de Galdakao, Galdakao, Spain; Biocruces Bizkaia Health Research Institute, Galdakao, Spain., Zabana Y; Gastroenterology Department, Hospital Universitari Mútua Terrassa, Barcelona, Spain; Center for Biomedical Research and Network in Liver and Digestive Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain., Barreiro-de Acosta M; Gastroenterology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Jazyk:	English; Spanish; Castilian
Zdroj:	Gastroenterologia y hepatologia [Gastroenterol Hepatol] 2022 Dec; Vol. 45 (10), pp. 737-741. Date of Electronic Publication: 2021 Aug 25.
DOI:	10.1016/j.gastrohep.2021.08.004
Abstrakt:	Introduction: Several vaccines against SARS-CoV-2 are currently in use and are recommended in inflammatory bowel disease (IBD) patients. Data are scarce about the gastroenterologists and IBD patient's acceptance of SARS-CoV-2 vaccines. The aim of the study was to evaluate the intention to get vaccination with SARS-CoV-2 vaccine among IBD patients from gastroenterologists and patient's perspective. Methods: An online anonymous survey was sent to 8000 patients from ACCU-Spain and 1000 members of the GETECCU. Three invitations were sent between October-December 2020. Descriptive analyses were performed, comparing physicians and patients responses by standard statistical analyses. Results: 144 gastroenterologists [63% female, mean age 43 years (SD 9.5)], and 1302 patients [72% female, mean age 43 years (SD 12)] responded to the survey. 95% of the physicians recommended SARS-CoV-2 vaccine for IBD patients and 87% consider that their vaccination strategies has not changed after the pandemic compared to 12% who considered that they currently refer more patients to vaccination. Regarding to IBD patients, only 43% of patients were willing to receive the vaccine and 43% were not sure. Male sex (p<0.001) and mesalazine treatment (p=0.021) were positively associated with SARS-CoV-2 vaccine acceptance. After multivariate analysis, only male sex was significantly associated with vaccination intent (OR=1.6; 95% confidence interval=1.2-2.0; p=0.001). Conclusions: Gastroenterologists and patient's perspective about SARS-CoV-2 are different. Future efforts to increase COVID-19 vaccine and decrease unfounded beliefs among IBD patients are needed. (Copyright © 2021 Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu